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ABSTRACT 
Objective: Determination and validation of a simple, sensitive and rapid reversed phase high-performance liquid chromatography method for the 
determination of itopride hydrochloride in human serum using nimesulide as an internal standard.  
Methods: A liquid-liquid extraction method was employed to extract itopride hydrochloride from serum matrix with diethyl ether. Chromatographic 
separation was obtained within 10 min using a reverse phase C18 column (250 mm×4.6 mm, 5 µm) with an isocratic elution. The mobile phase 
consisting of a mixture acetonitrile and 0.05M phosphate buffer with a flow rate of 1.0 ml/min was used and the eluents were monitored at 258 nm. 
Results: Calibration curves were linear (r2= 0.9987) in the range of 10ng/ml to 1000 ng/ml. The limit of quantitation was 14ng/ml. The mean 
recovery of itopride hydrochloride and the nimesulide from the biological matrix was more than 66.04 and 64.57%, respectively. The inter-day 
accuracy of the drug containing serum samples was more than 97.81% with a precision of 2.31–3.68%. The intra-day accuracy was 96.91% or more 
with a precision of 5.17–9.50%.  
Conclusion: The developed method was validated and successfully applied to a bioequivalence study in healthy human volunteers. 
Keywords: Itopride, Serum, Validation, UV-detection, Bioequivalence. 
 
INTRODUCTION 
Gastro-esophageal reflux disease (GERD) is one of the most prevalent 
upper gastrointestinal disorders. Itopride hydrochloride (IH) is 
primarily indicated in the treatment of GERD. IH is a novel 
gastroprokinetic agent which stimulates gastrointestinal motility 
through inhibition of dopamine D2 receptors and acetylcholine 
esterase. Chemically IH is (N-[4-[2-(dimethylamino)-ethoxy] benzyl]-
3,4-dimethoxybenzamide hydrochloride). IH is also prescribed for the 
treatment of gastrointestinal symptoms caused by reduced 
gastrointestinal motility, feeling of gastric fullness, upper abdominal 
pain, anorexia, heartburn, nausea and vomiting; non-ulcer dyspepsia 
or chronic gastritis [1]. Literature search revealed that few methods 
were reported for the determination of itopride hydrochloride in 
plasma and serum using fluorescent detection [2-5], LC-MS [6, 7], and 
a simultaneous determination of IH and domperidone using LC-MS [8]. 
So far, no methods have been reported using RP-HPLC with UV 
detection for the determination IH in human serum samples. The aim 
of the present investigation was to develop a simple, sensitive and 
rapid RP-HPLC method for the estimation of itopride hydrochloride in 
human serum and to validate the developed method based on the 
guidelines stated by the International Conference on Harmonization 
(ICH) for validation of analytical procedures [9]. The developed 
method was successfully applied to a bioequivalence study of itopride 
hydrochloride in healthy human volunteers.  
MATERIALS AND METHODS 
Materials 
Itopride hydrochloride (IH) and Nimesulide (NS), were obtained as 
gift samples from Sun Pharmaceuticals and Alembic limited, 
Vadodara, India, respectively. Acetonitrile (HPLC grade) and diethyl 
ether (HPLC grade) were purchased from Merck, Mumbai, India. 
Potassium di hydrogen orthophosphate (HPLC grade) was 
purchased from Hi Media, Mumbai. The water for HPLC was 
obtained by using TKA water purification system. 
Instrumentation 
The separations were performed on Shimadzu HPLC system 
consisting of LC-10AT and LC-10AT VP series pumps with SPD-10A 
UV–Visible spectrophotometric detector. The output signal was 
monitored and integrated using CLASS-VP Version 6.12 SPI 
software. The isocratic mode was selected and the oven and column 
temperature were maintained ambient. The chromatographic 
separations were performed on an Enable ODS–C18 column (25 cm X 
4.6 mm) with 5µ particle size using the mobile phase (ACN: 0.05 M 
KH2PO4, 50:50 v/v) flowing at the rate of 1.0 ml/min. Both the drug 
and internal standard were detected at 258 nm. 
Methods 
Collection of serum 
Freshly drawn blood was allowed to stand for 1 to 2 h at room 
temperature for clot formation. The clot was carefully separated 
from the wall of the tube with an applicator stick and then the tube 
was stored in a refrigerator for 12 to 24 h to permit clot contraction. 
The supernatant was decanted in to the clean tube and was 
centrifuged at 2500 rpm at about 4 oC for 30 min, and the serum was 
carefully removed from the tube by using a micro pipette.  
Since it is always desirable to have very clear serum, and often 
the serum from the first centrifugation contains a few 
erythrocytes or white cells, these cells were removed by 
repeated centrifugation as described above, to collect a clear 
serum free from cells [10]. 
Stock solutions and working solutions 
Stock solutions (1.0 mg/ml) of Itopride hydrochloride were 
prepared by dissolving 50.0 mg the pure drug in 50 ml of the diluent 
(Acetonitrile: buffer, 50:50 v/v). This stock solution was 
appropriately diluted with the above diluent to obtain the working 
solution of calibration standards with concentration of 0.1, 0.3, 0.5, 
1, 2, 3, 5 and 10µg/ml. Similarly, the working solutions for quality 
control standards (0.4, 4.0 and 8.0 µg/ml) were also prepared. In 
order to prepare the stock solutions (1.0 mg/ml) of internal 
standard, 50 mg of NS was dissolved in a mixture of 50 ml 
acetonitrile: buffer, 50:50(v/v). One milliliter of this solution was 
further diluted to 100 ml with the same diluent and a working 
solution of 10µg/ml was prepared.  
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Calibration standards and quality control samples 
Eight calibration standards ranging from 10 to 1000 ng/ml were 
prepared by adding 50 µl of known working solution of Itopride 
hydrochloride and 50 µl of internal standard solution to 450 µl of 
drug free human serum. The quality control samples were prepared 
in the manner similar to the calibration standard at three 
concentration levels: low, medium and high (40, 400 and 800 
ng/ml). During each run, six replicates of each concentration of 
quality control samples were extracted along with the calibration 
standards to check that the system performs in control. 
Sample preparation 
After adding 50 µl of internal standard to 500 µl of human serum 
samples, liquid-liquid extraction (LLE) was performed with the 
addition of 2.0 ml of diethyl ether. The sample was vortexes for 3.0 
min and allowed to settle for 10.0 min. About 1.0 ml of the 
supernatant was transferred to another test tube and was 
evaporated to dryness in a thermostatically controlled water bath 
maintained at 40 oC for 20 min. After drying, the residue was 
reconstituted with 200 µl of mobile phase and injected into the 
column. 
Method validation 
The developed chromatographic method was validated according to 
the procedures described in ICH Q2 (R1) guidelines. The following 
validation characteristics were addressed: linearity, specificity, 
detection and quantification limit, accuracy and precision, and 
recovery. 
Pharmacokinetic evaluation in human volunteers 
The developed method was applied to a cross-over single-dose two-
period study which compares the absorption pattern of itopride 
hydrochloride from two dosage forms, a plain matrix tablet (IMP3) 
and a layered matrix tablet(IMP3L2) tablet, administrated orally, 
under fasting conditions. The layered tablets were prepared to limit 
the initial drug release generally observed with highly water soluble 
drugs like Itopride hydrochloride and provide a zero order drug 
release profile compared to conventional single layer plain matrix 
tablets which provide a first order drug release profile. The study 
protocol was approved by the Institutional Ethics Committee of 
Roland Institute of Pharmaceutical Sciences, Berhampur, India 
(IEC/01).  
A total of eight healthy human male volunteers aged between 22 and 
35 y, gave written informed consent to participate in the study. All 
the volunteers participated in the study were non-smokers and did 
not drink alcohol. The nature and purpose of the study, and its 
possible consequences, was fully explained to them. An informed 
written consent was obtained from every volunteer. None of the 
volunteers were on drug treatment 1 w prior to participation in the 
study. The volunteers were free to withdraw from the study at their 
discretion. The volunteers were divided into 2 equal groups (Group I 
and Group II), and a crossover study was followed. Group I was 
administered with IMP3 tablets whereas Group II was administered 
with IMP3L2 tablets. After a washout period of 1week, Group I 
volunteers received IMP3L2 tablets and Group II volunteers 
received the IMP3 tablets. Both tablet formulations were 
administered with 240 ml of water after a 12-hour overnight fast. 
Food and drinks were withheld for at least 2 h after dosing. Blood 
samples were collected by direct venipuncture using a catheter hep 
lock over a period of 30 h (0, 1, 2, 3, 4, 6, 8, 10, 12, 24 and 30 h). The 
serum was separated, transferred to the labeled tubes and were 
stored at–20 °C, until analyzed. 
The pharmacokinetic parameters estimated were maximum 
concentration of drug in serum (Cmax), the time required for the drug 
to reach maximum concentration in the serum after drug 
administration (Tmax), absorption rate constant (Ka), the elimination 
rate constant (Ke), biological half-life (t1/2), area under the 
concentration time curve (AUC), and mean residence time (MRT). 
The maximum plasma concentration (Cmax) and the time required to 
reach Cmax (Tmax) were directly read from the arithmetic plot of time 
vs serum concentration of itopride hydrochloride. The overall 
elimination rate constant (ke) was calculated from the slope of the 
terminal elimination phase of a semi logarithmic plot of 
concentration vs time after subjecting it to linear regression analysis. 
The elimination half-life (t1/2) was obtained by dividing 0.693 with 
ke. The absorption rate constant (ka) was calculated using the 
method of residuals [11]. 
The observed variation in the pharmacokinetic parameters such as 
t1/2, Ka and MRT was tested using analysis of variance (ANOVA) with 
the help of Graph Pad Prism Software, version 4.00, 2003). The 
observed difference between mean pharmacokinetic parameters of 
Itopride hydrochloride from layered and plain matrix tablets was 
subjected to paired t-test’ to find the statistical significance. In all the 




Linearity was evaluated using freshly prepared spiked serum 
samples in the concentration range of 10-1000 ng/ml. Six replicates 
of linearity curves were analyzed. Samples were quantified using the 
ratio of peak area of drug to that of internal standard as an assay 
parameter. The linearity of the calibration curves was evaluated by 
the correlation coefficient, r². The mean correlation coefficient above 
0.99 was considered desirable for the calibration curves. The mean 
correlation coefficient (r2) for the calibration curves (n = 6) was 
found to be 0.9987, indicating that the relationship between 
response (y) and concentration (x) was linear (table 1). The 
equation of the mean calibration curve was Y = 0.0047X–0.0344. 
 




Concentration of Itopride 
hydrochloride (ng/ml) 
Peak area ratio 
(Drug/IS)* 
1 10 0.052±0.004 
2 30 0.149±0.007 
3 50 0.259±0.006 
4 100 0.463±0.009 
5 200 1.006±0.009 
6 300 1.496±0.018 
7 500 2.514±0.037 
8 1000 4.697±0.018 
n = 6 determinations, *mean±SD 
 
Detection and quantification limit  
The detection limit of an analytical procedure is the lowest amount 
of analyte in a sample which can be detected but not necessarily 
quantitated as an exact value. The quantification limit is the lowest 
amount of analyte in a sample which can be adequately determined 
with suitable precision and accuracy. The LOD and LOQ may be 
expressed as: LOD = 3.3 x σ/S and LOD = 10 x σ/S where σ = 
standard deviation of the Y-intercept of the mean calibration curve, 
S = slope of the mean calibration curve [12]. The detection and 
quantification limits of Itopride in human serum were determined at 
1.96 and 5.98 ng/ml, respectively. 
Specificity 
Specificity is the ability to assess the analyte in the presence of 
interfering components. It was assessed by comparing the 
chromatogram of blank serum with the chromatogram obtained of 
blank serum spiked with the drug, Itopride hydrochloride and 
internal standard, Nimesulide. Fig. 1 represents the chromatograms 
of IH and NS after the extraction of (A) blank serum and (B) serum of 
a human volunteer after intake of Itopride hydrochloride. 
Accuracy and precision 
The accuracy of an analytical procedure expresses the closeness of 
agreement between the true value and the determined value and is 
Sisinthy et al. 
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expressed as the percent agreement between the mean determined 
value and the true concentration. The accuracy was investigated at 
three concentration levels on serum spiked with known amounts of 
the analyte, then treating the resulting solution as indicated by the 
method. Each concentration was determined six times. The 
acceptance criteria are %RSD less than 15%.  
The precision expresses the closeness of agreement between 
repeated determinations Precision is expressed as the coefficient of 
variation (%) of a series of measurements of the  
 
 
Fig. 1: Representative Chromatogram of blank serum (A); and 
serum (B) of a human volunteer containing Itopride 
hydrochloride and Nimesulide (RT-2.62 min for Itopride 
hydrochloride; RT-9.167 min for Nimesulide) 
Calibration standards. The measurements were performed and 
evaluated. The acceptance criteria are %RSD less than 15 %. The 
recovery for inter-day accuracy was between 94.46 and 97.60% 
with the precision of 1.60-4.94% in human serum. The intraday 
accuracy was between 93.40 and 98.19 % with the precision of 2.79-
5.67 %. The mean accuracies (n=6) are listed in table 2. 
Recovery 
The recovery of itopride in human serum was determined for the 
calibration standards (at three concentration levels) and for the 
internal standard and can be expressed as the closeness of 
agreement (in %) between the areas of an extracted sample versus a 
non-extracted sample.  
Similarly the recovery of nimesulide, internal standard from 
human serum was also determined. According to the acceptance 
criteria set by the ICH guidelines, the extent of recovery of the 
drug and internal standard should be consistent, precise and 
reproducible. The mean recovery for itopride in human serum 
was between 72.82 and 74.08%. The mean recovery of 
nimesulide was 76.55% which was suitable for the assay. The 
mean recoveries (n=6) for the calibration standards and for the 
internal standard are shown in table 3. 
Statistical evaluation of pharmacokinetic parameters 
The developed method was applied to the determination of itopride 
hydrochloride in human serum in a pharmacokinetic study. Fig.2 has 
shown the mean itopride hydrochloride serum concentrations of 
IMP3 and IMP3L2. The pharmacokinetic parameters of this study 
are given in table 4. 
  
Table 2: Intra-day and Inter-day accuracy and precision studies of Itopride hydrochloride in human serum 
Quality control samples Concentration (ng/ml) Mean concentration found (ng/ml) %RSD % Accuracy  
Intra-day 
Low 40 37.78 4.94 94.46  
Medium 400 381.91 1.78 95.48  
High 800 780.81 1.60 97.60  
Inter-day 
Low 40 37.36 5.67 93.40  
Medium 400 383.37 3.02 95.84  
High 800 785.35 2.79 98.19  
n = 6 determinations 
 
Table 3: Mean recoveries of calibration standards and the internal standard 
Concentration (ng/ml) % Recovery %RSD  
Itopride hydrochloride 
40 72.82 3.97  
400 70.92 7.43  
800 74.08 4.21  
Nimesulide 
100 76.55 1.59  
n = 6 determinations 
 
DISCUSSION 
Quantitative determination of drugs and their metabolites in 
biologic fluids is crucial during drug discovery and development. 
Normally, plasma or serum is used to estimate the amount of the 
drug present in the body. Plasma is obtained by centrifuging the 
blood collected in a tube containing an anti-coagulant. Hence, 
plasma always contains one or more anticoagulants. Serum is a clear 
liquid that separates from blood when the blood is allowed to clot 
completely and then centrifuged. Therefore, serum contains no 
fibrinogen or no anticoagulants. Hence, serum is likely to have less 
interference compared to plasma in estimation of drug by HPLC. 
Literature search reveals few reports on the determination of IH in 
human plasma and human serum with fluorescent detection [2-8]. 
But, the estimation of IH in human serum with UV detection has not 
been exploited so far. In the present study, an attempt has been 
made to develop a HPLC method for the determination of IH with UV 
detection in human serum which is simple, sensitive and can be 
performed with a short chromatographic run time. 
The developed method was validated for linearity, specificity, 
accuracy and precisions, detection and quantification limits and 
recovery. The correlation coefficient of 0.9987 provided a very good 
correlation between the peak areas to that of IH concentration in 
serum indicating that the method is linear in the concentration 
range of 10-1000 ng/ml. As there were no interfering peaks 
observed at the retention times of IH and NS in the chromatograms 
after the extraction of (A) blank serum and (B) serum of a human 
volunteer after intake of Itopride hydrochloride (fig. 1), it was 
concluded that the method is selective to the determination of 
Sisinthy et al. 
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Itopride hydrochloride in human serum. The % RSD values obtained 
were found to be less than the official limit of 15% indicating that 
the developed is accurate and precise.  
The developed method was applied to the determination of itopride 
hydrochloride in human serum in a pharmacokinetics study. From 
fig. 2, it was apparent that prolonged absorption was achieved with 
both the matrices, IMP3 (plain matrix tablet) and IMP3L2 (three 
layer matrix tables). More rapid early absorption observed for the 
plain matrix tablet can be attributed to higher initial release due to 
non-linear release as well as overall higher release rate when 
compared to the layered matrix tablet. 
 
 
Fig. 2: Mean serum levels of Itopride hydrochloride following 
administration (mean±SD) from plain (IMP3) and layered 
(IMP3L2) matrix tablets 
 
Form table 4it was found that the absorption rate constant (Ka) of 
the drug from plain matrix tablet is 0.078±0.007 h-1 and that 
obtained from layered matrix tablet is 0.049±0.005 h-1, and the 
difference in the value of absorption rate constant is statistically 
significant [p value = 0.0006 (Group A) and 0.001 (Group B)]. Thus 
the prolonged Tmax and decreased Ka of Itopride hydrochloride in 
case of layered tablets indicated that the drug release are retarded, 
providing a prolonged and controlled in vivo delivery.  
The AUC 0-∞ was found to be3647.42±157.73 and 3521.89±112.6 for 
IMP3 and IMP3L2 respectively. As there is no significant difference 
[p value = 0.1451 (Group A) and 0.5934 (Group B)] between the AUC0-
∞of plain and layered matrix tablets, it can be said that the 
bioavailability of Itopride hydrochloride from both the matrices is 
almost similar. The elimination half-lives (t1/2) of Itopride 
hydrochloride following oral ingestion of the plain and layered 
matrix tablet were 8.19±0.86 and 10.47±0.87 h respectively, which 
are statistically significant [p value = 0.005 (Group A) and 0.00445 
(Group B)]. Thus the prolonged t1/2 indicates that the release from 
the layered tablet is slow compared to that of the plain matrix tablet. 
The mean residence time (MRT) of Itopride hydrochloride of the 
plain and layered matrix tablet was 11.91±0.512 and 14.19±0.67 h 
respectively, which are statistically significant [p value = 0.0008 
(Group A) and 0.0022 (Group B)]. These results indicate that in case 
of layered tablet the drug stays for more time in the body when 
compared to plain matrix tablet as the drug is slowly released from 
the layered tablet compared to that of the plain matrix tablet. The 
above study concludes that the developed HPLC method was 
successfully applied to a pharmacokinetics study and can be used in 
the analysis of biological samples. 
CONCLUSION 
A simple, sensitive and rapid bioanalytical method for the estimation 
of Itopride in serum samples has been developed. The method 
involved a single step liquid-liquid extraction procedure followed by 
chromatographic separation on a reversed phase HPLC column with 
an UV detector. The method was validated and satisfied the 
requirement of linearity, accuracy and precision for estimation in 
serum as per ICH guidelines. The developed method was 
successfully applied to a bioequivalence study in human volunteers. 
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